Opioid Agonist Therapy
BehavioralOpioid Agonist Therapy (OAT) as HIV prevention
NCT Number: NCT06962033
The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utilizing latent class growth analyses in people who inject drugs (PWID).
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Alternative Georgia, Tbilisi, Georgia
Aim 1 consists of the development of NIATx learning collaboratives with prison OAT providers (addiction care specialists or primary care doctors). This aim is an implementation science aim involving the collection of OAT scale-up data from each country's national OAT database, as well as administration of survey to prison narcologists every 6 months.
Aim 2 consists of the development of NIATx learning collaboratives with probation and prison officers in Kyrgyzstan, Tajikistan, Moldova, and Georgia. Investigators will collect OAT scale-up data from each member country's national OAT database, and administer a survey to probation officers every 6 months. Investigators will also observe and interview probation clients and staff using ethnographic methods.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Aim 1:
Aim 2:
Exclusion criteria
-
Opioid Agonist Therapy (OAT) as HIV prevention
Time frame: baseline up to 4 years
Number of patients receiving opioid agonist therapy (OAT) per OAT site.
Time frame: baseline up to 4 years
Adherence to NIATx protocol: using the NIATx fidelity scale, a 19-item assesment to measure adherence to the NIATx model on a 5-point scale from 1 (No evidence) to 5 (Extensive evidence).
Contact information is provided by the study sponsor or research team.
David Oliveros, MPH
CONTACT
Jin Hee Kim, MPH
CONTACT
Yale University
Other
Acronym: PRIDE III
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04521920
Acquired Immunodeficiency Syndrome, Behavior
Charlotte, North Carolina, United States
View Trial DetailsNCT05108935
Acquired Immunodeficiency Syndrome, Behavior
Durham, North Carolina, United States
View Trial DetailsNCT05419024
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Bethesda, Maryland, United States
View Trial DetailsNCT00006518
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Bethesda, Maryland, United States
View Trial Details